Flow cytometric analysis of SSEA4 expression on NTERA-2 cells. Cells from the NTERA-2 (Right) or HeLa (Human cervix adenocarcinoma epithelial cell, Left) was stained with either Alexa Fluor® 647 Mouse IgG Isotype Control (Black line histogram) or SDT SSEA4 Recombinant Mouse mAb (Alexa Fluor® 647 Conjugate) (Red line histogram) at 1/320 (0.25 μg), cells without incubation with primary antibody and secondary antibody (Blue line histogram) was used as unlabelled control. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
SSEA4 Recombinant Mouse mAb (Alexa Fluor® 647 Conjugate) (S-R541)
SSEA4 Recombinant Mouse mAb (Alexa Fluor® 647 Conjugate) (S-R541)
Price:
Regular price
$180 USD
Regular price
Sale price
$180 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Synonyms | SSEA-4; stage-specific embryonic antigen 4 |
| Clone Number | S-R541 |
| Antibody Type | Mouse mAb |
| Application | ICC, FCM |
| Reactivity | Hu |
| Purification | Protein A |
| Concentration | 0.8 mg/ml |
| Conjugation | Alexa Fluor® 647 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
| application | dilution | species |
| ICC | 1:100 | Hu |
| FCM | 1:320 | Hu |
Background
The SSEA-4 (Stage-Specific Embryonic Antigen-4) is a significant glycolipid antigen belonging to the Globo series glycosphingolipids (such as Gb5 and SSEA-3). Its structural characteristic is Neu5Gcα2-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-Cer. It is highly expressed during early embryonic development (e.g., in morula and blastocyst stages) and in pluripotent stem cells (such as human embryonic stem cells, hESCs, and induced pluripotent stem cells, iPSCs), making it a widely used surface marker for pluripotency. Additionally, SSEA-4 is aberrantly expressed in various cancers (e.g., breast cancer, lung cancer, gliomas) and is associated with tumor progression, metastasis, and immune evasion, potentially through the regulation of cell adhesion or signaling pathways (e.g., EGFR/ERK). Notably, since humans lack the enzyme to synthesize its sialic acid component (Neu5Gc), SSEA-4 expression may rely on exogenous uptake or non-canonical biosynthetic pathways. This unique feature also presents a potential therapeutic target for cancer treatment.
Picture
Picture
FC
Immunocytochemistry
ICC shows positive staining in NTERA-2 cells. Anti-SSEA4 (Alexa Fluor® 647 Conjugate) antibody was used at 1/100 dilution (meganta) and incubated overnight at 4°C. The cells were fixed with 4% PFA and permeabilized with 0.1% PBS-Triton X-100. Nuclei were counterstained with DAPI (Blue).
ICC shows negative staining in HeLa cells. Anti- SSEA4 (Alexa Fluor® 647 Conjugate) antibody was used at 1/100 dilution and incubated overnight at 4°C. The cells were fixed with 4% PFA and permeabilized with 0.1% PBS-Triton X-100. Nuclei were counterstained with DAPI (Blue).
